Fosun Pharma stock gained 2.69 percent on September 30 as H1 revenue rose

Published on 10/07/2026 at 06:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fosun Pharma stock reflects CNY 20.442 billion of H1 2026 revenue, up 4.75 percent year over year. Innovative-drug revenue rose 13.84 percent, while the consensus target is CNY 33.64.

Fosun Pharma, CNE100001M79, Illustration mit AI erstellt.

Fosun Pharma (CNE100001M79) gained 2.69 percent to CNY 24.02 on the Shanghai Stock Exchange on September 30, 2026. The move followed a first-half update in which Seeking Alpha reported revenue of CNY 20.442 billion for H1 2026, up 4.75 percent from the prior-year period.

Revenue growth meets innovation

The H1 performance was led by newer products rather than a broad revenue surge. Innovative-drug revenue reached CNY 4.911 billion, an increase of 13.84 percent year over year, according to Seeking Alpha in its account of the September 22, 2026 interim-results briefing.

Research spending also accelerated. Fosun Pharma reported total R&D expenditure of CNY 3.247 billion for H1 2026, up 25.66 percent year over year, while overseas revenue increased 16.45 percent in the same period, Seeking Alpha reported.

Analysts see more upside

The market's forward benchmark is higher than the latest Shanghai quote. Investing.com lists a Buy consensus based on five analysts, with an average 12-month target of CNY 33.64, a high target of CNY 44.00 and a low target of CNY 24.80.

Using the CNY 24.02 Shanghai reference price, the average target lies 40.05 percent above the price. The range matters because the low target is only CNY 0.78 above the latest quote, while the high target is CNY 19.98 higher.

Stock remains below yearly high

Fosun Pharma's CNY 24.02 price stood inside its CNY 20.85 to CNY 30.09 52-week range on September 30, 2026. The stock was 20.17 percent below the 52-week high, leaving the earnings trajectory and the delivery of innovative products as the key variables behind the valuation gap.

Volume reached 36,991,839 shares on the same Shanghai session, while market capitalization stood at CNY 63.4 billion. Fosun Pharma's primary listing is the Shanghai Stock Exchange, and its business spans pharmaceutical manufacturing, medical devices, diagnostics and healthcare services, according to Fosun Pharma.